EU Blow For Alzheimer’s Drug Leqembi; Eisai To Appeal

The EMA says the benefits of treatment with Leqembi are not large enough to outweigh its risks. Meanwhile, Alzheimer Europe is hoping that real-world findings from the US-mandated patient registry or from ongoing trials will help persuade the EU regulator to reconsider its position.

The Alzheimer’s disease drug Leqembi is already approved in the US, Japan, China, South Korea, Hong Kong and Israel • Source: Shutterstock

Eisai and Biogen are to appeal against the European Medicines Agency’s recommendation to refuse EU marketing approval for their Alzheimer’s disease (AD) drug Leqembi (lecanemab), which is already approved in the US, Japan, China, South Korea, Hong Kong and Israel.

Key Takeaways

  • The CHMP rejected Leqembi because it considered that the observed effect of the drug on delaying cognitive decline did not counterbalance the risk of serious side events associated with the medicine, in particular the frequent occurrence of amyloid-related imaging abnormalities (ARIA).

The rejection was announced by the EMA today, after the agency’s human medicines committee, the CHMP, adopted a negative opinion...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet